Your browser doesn't support javascript.
loading
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
Ferraro, Sara; Cappello, Emiliano; Bartolini, Claudia; Convertino, Irma; Bertani, Lorenzo; Lucenteforte, Ersilia; Costa, Francesco; Paoletti, Olga; Giometto, Sabrina; Gini, Rosa; Tuccori, Marco.
Afiliación
  • Ferraro S; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa.
  • Cappello E; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa.
  • Bartolini C; Osservatorio di Epidemiologia, Agenzia Regionale di Sanità della Toscana, Firenze.
  • Convertino I; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa.
  • Bertani L; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa.
  • Lucenteforte E; Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa.
  • Costa F; Department of General Surgery and Gastroenterology, Pisa University Hospital.
  • Paoletti O; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa.
  • Giometto S; Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa.
  • Gini R; Osservatorio di Epidemiologia, Agenzia Regionale di Sanità della Toscana, Firenze.
  • Tuccori M; Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa.
Eur J Gastroenterol Hepatol ; 35(11): 1263-1269, 2023 11 01.
Article en En | MEDLINE | ID: mdl-37724478
BACKGROUND: A missed diagnosis of Crohn's disease (CD) can delay treatment initiation with consequences on disease course. AIMS: To measure the possible impact of missed diagnoses on drug utilization and access to healthcare facilities in a real-world cohort of CD patients. METHODS: This retrospective observational study has been conducted on the regional administrative databases of Tuscany (Italy). We included patients with a first record of CD diagnosis between 06/11/2011 and 06/30/2016. Possible missed diagnosis (exposure) was defined by hospital presentation for gastrointestinal symptoms consistent with CD diagnosis that occurred in the 7-60 months preceding CD diagnosis. We compared exposed and non-exposed patients by assessing time-free from biologic drugs and from Emergency Department (ED) or hospital access. Hazard ratio (HR) was calculated using Cox models. RESULTS: Among 3342 CD patients, 584 (17.5%) had a possible missed diagnosis. A risk of being treated with biologic drugs [adjusted HR (aHR): 2.17, 95% CI: 1.75-2.71] and of access to ED or hospitalization (aHR: 1.59, 95% CI: 1.44-1.75) was observed in patients with a possible missed diagnosis as compared to those without. CONCLUSION: Tertiary care caregivers should be trained in the identification of early CD symptoms, to timely identify CD diagnosis and optimize pharmacological treatment and disease management.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Enfermedad de Crohn Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Enfermedad de Crohn Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Humans Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article